6Yuen GJ,Morris DM,MydlowPK.Pharmacokinetics,absolute bioavailability and absorption characteristics oflamivudine.J Clin Pharmacol,1995,35(12):1174-1180
7Angel JB,Hussey EK,Hall ST.Pharmacokinetics of 3TC (GR109714X) administered withand without food to HIV-infected patients.Drug invest,1993,6(1):70-74
8Tyrrell DLJ,Mitchell MC,De Man RA.Phase Ⅱ trail of lamivudine for chrinichepatitis B.Hepatology,1993,18(4Pt):112A
9Van leeuwen R,lange JMA,Hussey EK.The safety and pharmacokinetics of a reversetranscriptase inhibitor,3TC,in subjects with HIV indection:a phase Ⅰstudy.AIDS,1992,6(12):1417-1425
10Johnson MA,Horak J,Breuel P.The pharmacokinetics of lamivudine in patients withimpaired hepatic function.Eur J Clin pharmacol,1998,54(4):363-366
